Cost Effectiveness of Venous Leg Ulcer Healing Using Muscle Pump Activation Authors: Michael C. Stacey, Connie Harris, Amanda Loney, Graham Corke Published: 2026 ABSTRACT ABSTRACTThe aim of this study was to evaluate the cost‐effectiveness of treating patients with Venous Leg Ulcers (VLUs) with the Muscle Pump Activation device (MPA, geko) in Canada. This is a cost‐effectiveness analysis of the treatment of patients with VLUs, using MPA for 4 weeks in addition to standard of care compression therapy (SOC), compared to SOC alone using Canadian costs of VLU treatment. The authors determined the Canadian costs for each visit for a patient with a VLU to have their dressings performed at a nursing clinic. The total costs of treatment were determined based on healing rates from a randomized controlled trial from Wales that demonstrated a significant improvement in the healing of VLUs when MPA was used for 4 weeks in addition to SOC, compared to SOC alone. The cost per visit to a nursing clinic for the treatment of a VLU was estimated to be $109.71 CAD and dressing frequency was estimated to be an average of every 2.5 days. Using projected healing rates over a 12‐month period based on the UK paper, the model indicated that treatment with MPA resulted in a cost savings of $983.61 CAD per patient. The average increase in ulcer free days was 56.6 days per patient. The Incremental Cost Effectiveness Ratio (ICER) identified a saving of $17.38 per ulcer free day. This model based on Canadian costs resulted in faster healing of VLUs and a reduced average Direct Wound Care Cost of $983.61 per patient for the whole of their ulcer treatment when the MPA is used for 4 weeks in addition to SOC. This treatment has the potential for patient benefit as well as significant cost savings for the Canadian Health Care system. Introduction Chronic venous insufficiency (CVI) is caused by ambulatory venous hypertension that can be secondary to venous valve failure, venous reflux, insufficient venous return and/or post‐thrombotic syndrome [1, 2, 3]. Early pathological changes such as telangiectasia, varicose veins, discomfort and lower leg edema, can progress to skin involvement including hemosiderin deposits, lipodermatosclerosis, and/or stasis dermatitis [4]. Calf‐muscle pump failure is found in up to 55% of patients with CVI [5] and along with the skin changes, contributes to venous leg ulcers (VLUs) which are the most advanced complication of CVI. Usually located on the medial lower third of the calf, a VLU has an irregular shape with a granular base that may contain mixed tissue including slough, fibrin and granulation, and is frequently accompanied by extreme burning pain [6]. Often chronic, VLUs are a significant challenge to patients with slow healing times (93% in 12 months, 7% > 5 years) and high recurrence rates (70% at 3 months) [7]. VLU Treatment In addition to local wound management following the principles of Wound Bed Preparation [8, 9], the key best practice/standard of care (SOC) intervention in the treatment of VLUs [10] is high compression therapy over the calf, optimally at 30–40 mmHg, to decrease edema, venous distension, venous hypertension and improve impaired calf muscle pump function [11]. There are many options available: multilayer bandaging systems, elastic or inelastic bandages, compression stockings, inelastic or short stretch wraps with hook and loop closures, cut‐to‐length elasticized tubing, and intermittent pneumatic compression (IPC), each designed to improve patient outcomes, safety and tolerance [12]. They have very different functionality and vary significantly in their ability to deliver and maintain optimal compression. For example, cut‐to‐length elasticized tubing typically does not achieve the recommended 30–40 mmHg pressure. Therefore, careful assessment is essential to match the right product to each patient's needs. No single system has proven universally superior for healing VLU [7, 13, 14], and individualized selection remains critical to optimizing outcomes, safety, and patient tolerance. Dressing formularies often do not contain a complete range of options, and the need for compression systems to be applied correctly further compounds the difficulty of achieving effective compression [15]. Non‐adherence to optimal compression therapy in the real world is estimated to affect up to 80% of people with VLU [16] with discomfort, pain, quality of life, hygiene, and lack of knowledge being frequent reasons [17, 18]. Even in the randomized controlled Canadian Bandaging Trial, with small cohorts of specially trained Registered Nurses applying either a four layer or short‐stretch system of high compression therapy, non‐adherence was still approximately 24%, with reasons including skin reactions, discomfort, skin breakdown, or bandaging applied too tight or too loose [19]. Without optimal compression, VLUs become more chronic, with infections, progression of CVI, increased pain, decreased mobility and a statistically significant difference in healing rates when compression is used compared with no compression [7]. Costs of VLU Treatment Dressing and compression bandaging changes two to three times per week, usually in nursing clinics by a trained nurse, represent the key components of the direct costs of treating VLUs, with nursing being the largest cost [20]. Only a very small proportion of patients require admission to hospital due to complications of the VLU or for surgical correction or endovascular venous procedures (the main therapeutic options) and would in most cases be for a short period [21]. Although data is limited in western countries, care of VLU in Wales is estimated at 1.2% of the total healthcare budget [20]. Costs for treating unhealed ulcers is estimated to be 4.5 times higher than for those that heal within 12 months [22]. In addition, there are the patient costs—loss of productive work time, costs of travel, parking and possibly the costs of dressings and compression systems. The different home care systems in the provinces of Canada also impact the costs of treating patients with VLU and the potential cost savings of more rapid VLU healing [23]. Future Challenges VLUs account for 80%–85% of all leg ulcers [4] affecting 1% to 2% of the population in western societies, increasing to ≤ 4% for those aged > 65 years [24]. With aging, the proportion of the Canadian population over 65 years of age is expected to increase from 18.9% of the population in 2023 to between 23% and 25% of total population by 2036 [25]. As the population ages, the number of patients with VLUs will increase, taxing the demand for nursing care, when there is already a national [26] and global nursing shortage [27]. New therapies that could decrease time to healing even faster than with optimal compression therapy would have significant quality of life benefits for patients, improving their productivity in work or in contributions to the community, and reducing any direct costs they incur for obtaining treatment [28]. For the health care system, it would result in reduced direct costs both in dressing materials and nursing costs, and would increase capacity of nursing to treat other patients in need of care without having to increase budgets [28]. To support informed funding decisions, it is important to estimate the cost of the new therapies against their expected clinical benefits. Ideally, faster healing of VLUs should lead to savings that outweigh the initial investment. Muscle Pump Activation (MPA) Therapy In the 2024 Canadian Consensus Statement on the management of Venous Leg Ulcers [29] a muscle‐pump activator (MPA) (geko Wound Therapy—Firstkind Ltd., United Kingdom) is recommended for treatment of venous leg ulcers when a patient with an ABPI of > 0.5 cannot tolerate optimal or indeed any compression therapy, or if not on a healing trajectory—no size reduction in 2 to 4 weeks, or reduction less than 30% at 4 weeks after initiating SOC treatment. The MPA device is wrist‐watch sized, self‐adhesive and battery powered, worn just below the knee at the fibular head where it stimulates the common peroneal nerve, resulting in foot eversion, toe extension and foot dorsiflexion. This causes passive stretching of the calf flexor muscles [30], improving calf muscle pump function [31]. Use of the device has been proven to increase both wound bed and peri‐wound microvascular blood flow in patients with venous and mixed venous/arterial disease ulcers [32]. In a recent randomized controlled trial (RCT) based in Cardiff, United Kingdom (UK), the use of this MPA 12 h per day for 4‐weeks, in combination with a multilayer compression system in patients with VLUs resulted in a significant two‐fold increase in wound healing compared to the use of the multilayer compression therapy alone over a 4‐month period [33]. Healing rates at 12 weeks post‐intervention were reported as 42% for the SOC plus MPA group and 27% for the SOC group alone. A cost–benefit analysis published after the RCT estimated that integrating the MPA device into SOC protocols would reduce the overall NHS expenditure on VLU wound management by as much as 15% [34]. Actual Canadian costs of VLU care are not currently tracked as they are in the NHS in the UK. Objective of This Paper The objective of this paper is to develop a cost–benefit analysis model for the treatment of VLUs in the community using the MPA device within the Canadian healthcare context. By integrating healing data from the Cardiff RCT with estimated treatment costs in Canada, we aim to evaluate whether the use of MPA in combination with standard compression therapy (SOC) offers potential cost savings. This analysis is intended to support healthcare funders in making informed decisions about adopting MPA therapy for patients with VLUs. Methods This is health economic study to assess the impact of the MPA therapy on VLU treatment by determining the Incremental Cost Effectiveness Ratio (ICER) [35]. The ICER is calculated from the potential increment of ulcer free days (UFD) resulting from the use of the MPA therapy in addition to SOC and the potential cost reduction that comes from that. The key components of that determination are the published healing rates in the Cardiff RCT for SOC compared to SOC and MPA; the duration of treatment with MPA in the model; and the estimated Canadian costs of SOC treatment of patients with VLU. Estimated Costs of VLU Treatment The costs of VLU treatment can be broken down into Direct and Indirect costs [36]. Direct costs can be considered as those related to providing wound care and those related to additional Institutional or System expenses. The costs of treatment can be considered as: Direct Costs ○ Wound Care Costs—treatment as part of regular wound care including costs of dressings, associated dressing materials and disposables, compression systems, nursing and clinical care, and associated travel.○ Institutional/System Costs—costs of physician wound assessments, treatment outside regular care including emergency visits, diagnostic test costs, treatment of infection, hospital admissions, facilities overhead. Indirect Costs (Societal costs)—patient waiting and travel time, loss of work, paid or unpaid caregiver costs, prescription and non‐prescription medications and treatments. Direct Costs ○ Wound Care Costs—treatment as part of regular wound care including costs of dressings, associated dressing materials and disposables, compression systems, nursing and clinical care, and associated travel.○ Institutional/System Costs—costs of physician wound assessments, treatment outside regular care including emergency visits, diagnostic test costs, treatment of infection, hospital admissions, facilities overhead. Direct Costs ○ Wound Care Costs—treatment as part of regular wound care including costs of dressings, associated dressing materials and disposables, compression systems, nursing and clinical care, and associated travel.○ Institutional/System Costs—costs of physician wound assessments, treatment outside regular care including emergency visits, diagnostic test costs, treatment of infection, hospital admissions, facilities overhead. ○ Wound Care Costs—treatment as part of regular wound care including costs of dressings, associated dressing materials and disposables, compression systems, nursing and clinical care, and associated travel. Wound Care Costs—treatment as part of regular wound care including costs of dressings, associated dressing materials and disposables, compression systems, nursing and clinical care, and associated travel. ○ Institutional/System Costs—costs of physician wound assessments, treatment outside regular care including emergency visits, diagnostic test costs, treatment of infection, hospital admissions, facilities overhead. Institutional/System Costs—costs of physician wound assessments, treatment outside regular care including emergency visits, diagnostic test costs, treatment of infection, hospital admissions, facilities overhead. Indirect Costs (Societal costs)—patient waiting and travel time, loss of work, paid or unpaid caregiver costs, prescription and non‐prescription medications and treatments. Indirect Costs (Societal costs)—patient waiting and travel time, loss of work, paid or unpaid caregiver costs, prescription and non‐prescription medications and treatments. All three components of costs can be considered in these analyses. We have specifically assessed the Direct Wound Care Costs alone in order to assist the funders of community care to be able to evaluate the cost benefit of funding MPA for patients with VLU. To obtain an estimate of the overall real costs, we plan in future studies to evaluate the total cost including all Direct Costs and Indirect Costs. In Canada the treatment of VLU occurs predominantly in the community [19] and for the funders of community health care, the key ICER analysis that they are concerned with is that related to Direct Wound Care Costs. In this study we have obtained data on Canadian costs in relation to the Direct Wound Care Costs and have determined the potential costs per patient visit. There is no database on the costs of treating wounds in the community in Canada. The costs were determined from accessible data on nursing salaries and dressing materials across Canada, on feedback from other healthcare professionals who treat patients with VLUs, and from the authors own experience. This analysis was based on patients with VLUs who have no other complicating factors contributing to their impaired VLU healing, which aligns with the patient cohort who participated in the Cardiff RCT [33]. In addition, the assumption was that these patients could attend a nursing clinic for their dressings and did not require a nurse to attend in their home to do the dressings. The cost of providing 4 weeks of MPA treatment for one leg at the time of this study was $1500 CAD (Perfuse Medtec Inc., London, Ontario, Canada). Projected Healing Rates and Incremental Cost‐Effectiveness Ratio (ICER) The incremental cost‐effectiveness ratio (ICER) is derived from healing data reported in the Cardiff RCT, which tracked ulcer healing from Day 0 to Day 120. These healing rates were modelled using an instantaneous exponential ulcer decay function to project outcomes over a 12‐month period (Day 0 to Day 365)– this function describes continuous reduction in the number of VLUs where the rate of change at any moment is directly proportional to the current quantity. Statistically, this approach aligns with an exponential probability distribution (this models the time between events in a Poisson process with events happening continuously at a constant average rate), which is a simplified form of the more representative two‐parameter Weibull distribution [37]. The instantaneous exponential ulcer decay function is used to forecast the percentage of ulcers remaining after 1 year or 365 days. Based on the Cardiff RCT, the force decline is calculated as −0.002623 for SOC, and −0.004540 for the SOC and MPA. Using these forecasts, ulcers remaining after 1 year of treatment are 38.40% for the SOC and 19.07% for SOC and MPA. In order to calculate the incremental cost‐effectiveness ratio (ICER), two increments are required—the incremental cost or difference between the two treatments, and the incremental increase in ulcer free days (UFD) between the two treatments. First, we computed the incremental cost or difference in the VLU treatment cost for SOC with MPA (SOC and MPA) and the VLU treatment for SOC alone over the treatment period. The MPA device is used for 4 weeks, 12 h a day, and SOC is applied to both treatment groups in the same four‐week period, and SOC is applied for the remainder of the patient treatment in both treatment regimes. Treatment is continued until ulcer healing or for up to 1 year in this analysis. Cost savings due to SOC and MPA result from fewer days of SOC treatment in this analysis—more ulcer free days (UFDs). From this cost saving is subtracted the four‐week MPA cost, to produce the incremental cost saving due to SOC and MPA. The SOC and MPA treatment produces more UFDs as a result of an approximately 19% increase in healing rate over SOC alone. The ICER is then calculated as a cost decrease or cost increase due to SOC and MPA therapy divided by the increase or decrease in UFD. The result is a cost or saving per ulcer free day. The ideal Win‐Win ratio is a cost decrease per incremental UFD. In this analysis, the Canadian costs of VLU treatment were applied to an additional group of patients with VLUs that have required treatment for longer than 12 months due to the ulcers not healing. Unpublished data from FirstKind Ltd., UK have indicated that with continuous use of MPA, these patients will heal their VLUs in an average of 60 days, compared to ongoing VLU treatment without healing. These cost benefits were also applied to population estimates for the number of patients with VLUs in Ontario and the whole of Canada. Published estimates on the proportion of patients with VLUs that remain unhealed for 12 months [38, 39, 40] were also used to determine this patient population for Ontario and for Canada. Results Estimated Costs of VLU Treatment In determining the costs of VLU treatment, a number of key determinations were made from the data gathered. These included: Feedback from clinicians who treat patients with VLUs was that a dressing change will occur on average every 2.5 days in patients who have VLUs with no complicating factors. This is also based on these patients being able to attend a nursing clinic and not requiring a nurse to attend at their home. Some will need more frequent dressings initially and most will ultimately progress to every third day or twice weekly dressings. This dressing frequency reflects the real practice of treating patients with VLUs, rather than the ideal best practice of dressing changes less frequentlyThe time per patient visit, as determined by our panel, varies with the type of nurse involved, and the frequency with which different nurses provide care. These were estimated as: ○30 min for Registered Practical Nurse (RPN)—80% of patient dressings○1 h for Nurses Specialized in Wound Ostomy and Continence (NSWOC) trained Registered Nurse (RN)—10% of patient visits○1 h for Registered Nurse (RN)—10% of patient visits Nursing time was based on nurses working 7.5 h of patient care per day for 42 weeks per year which allowed time to be allocated to holidays, professional development, unit meetings, and other administrative functions. The nursing cost is based on an estimate of the salaries for the different nursing positions, plus 30% for additional employment expenses beyond salaries and assuming that there is the equivalent of 42 weeks of direct patient care.Costs of dressing materials—rather than attempt to describe best practices, the authors aimed to capture the average costs associated with compression systems and different types of dressings that are used in patients with VLUs in Canada. These included ○Multilayer compression bandage system○A contact layer which may be variable and an average cost has been estimated○An absorbent layer—an average cost has been estimated○A dressing pack and cleansing solution cost has been estimated MPA cost was determined on 4 weeks use for 12 h per day, as was used in the Cardiff RCT. Feedback from clinicians who treat patients with VLUs was that a dressing change will occur on average every 2.5 days in patients who have VLUs with no complicating factors. This is also based on these patients being able to attend a nursing clinic and not requiring a nurse to attend at their home. Some will need more frequent dressings initially and most will ultimately progress to every third day or twice weekly dressings. This dressing frequency reflects the real practice of treating patients with VLUs, rather than the ideal best practice of dressing changes less frequently Feedback from clinicians who treat patients with VLUs was that a dressing change will occur on average every 2.5 days in patients who have VLUs with no complicating factors. This is also based on these patients being able to attend a nursing clinic and not requiring a nurse to attend at their home. Some will need more frequent dressings initially and most will ultimately progress to every third day or twice weekly dressings. This dressing frequency reflects the real practice of treating patients with VLUs, rather than the ideal best practice of dressing changes less frequently The time per patient visit, as determined by our panel, varies with the type of nurse involved, and the frequency with which different nurses provide care. These were estimated as: ○30 min for Registered Practical Nurse (RPN)—80% of patient dressings○1 h for Nurses Specialized in Wound Ostomy and Continence (NSWOC) trained Registered Nurse (RN)—10% of patient visits○1 h for Registered Nurse (RN)—10% of patient visits The time per patient visit, as determined by our panel, varies with the type of nurse involved, and the frequency with which different nurses provide care. These were estimated as: ○30 min for Registered Practical Nurse (RPN)—80% of patient dressings○1 h for Nurses Specialized in Wound Ostomy and Continence (NSWOC) trained Registered Nurse (RN)—10% of patient visits○1 h for Registered Nurse (RN)—10% of patient visits ○30 min for Registered Practical Nurse (RPN)—80% of patient dressings 30 min for Registered Practical Nurse (RPN)—80% of patient dressings ○1 h for Nurses Specialized in Wound Ostomy and Continence (NSWOC) trained Registered Nurse (RN)—10% of patient visits 1 h for Nurses Specialized in Wound Ostomy and Continence (NSWOC) trained Registered Nurse (RN)—10% of patient visits ○1 h for Registered Nurse (RN)—10% of patient visits 1 h for Registered Nurse (RN)—10% of patient visits Nursing time was based on nurses working 7.5 h of patient care per day for 42 weeks per year which allowed time to be allocated to holidays, professional development, unit meetings, and other administrative functions. The nursing cost is based on an estimate of the salaries for the different nursing positions, plus 30% for additional employment expenses beyond salaries and assuming that there is the equivalent of 42 weeks of direct patient care. Nursing time was based on nurses working 7.5 h of patient care per day for 42 weeks per year which allowed time to be allocated to holidays, professional development, unit meetings, and other administrative functions. The nursing cost is based on an estimate of the salaries for the different nursing positions, plus 30% for additional employment expenses beyond salaries and assuming that there is the equivalent of 42 weeks of direct patient care. Costs of dressing materials—rather than attempt to describe best practices, the authors aimed to capture the average costs associated with compression systems and different types of dressings that are used in patients with VLUs in Canada. These included ○Multilayer compression bandage system○A contact layer which may be variable and an average cost has been estimated○An absorbent layer—an average cost has been estimated○A dressing pack and cleansing solution cost has been estimated Costs of dressing materials—rather than attempt to describe best practices, the authors aimed to capture the average costs associated with compression systems and different types of dressings that are used in patients with VLUs in Canada. These included ○Multilayer compression bandage system○A contact layer which may be variable and an average cost has been estimated○An absorbent layer—an average cost has been estimated○A dressing pack and cleansing solution cost has been estimated ○Multilayer compression bandage system Multilayer compression bandage system ○A contact layer which may be variable and an average cost has been estimated A contact layer which may be variable and an average cost has been estimated ○An absorbent layer—an average cost has been estimated An absorbent layer—an average cost has been estimated ○A dressing pack and cleansing solution cost has been estimated A dressing pack and cleansing solution cost has been estimated MPA cost was determined on 4 weeks use for 12 h per day, as was used in the Cardiff RCT. MPA cost was determined on 4 weeks use for 12 h per day, as was used in the Cardiff RCT. The potential Direct Costs for SOC are shown in Table 1. The daily costs were determined based on a dressing treatment every 2.5 days. TABLE 1Direct treatment SOC costs.Cost itemSOC cost per visitDaily costNursing costsNurse levelAverage salary+30% oncosts.Cost per hourNSWOCC115 000.149 500.94.93RN90 000117 00074.28RPN65 00084 50053.65Average nursing cost per visit based on frequency and duration for different nursing levels−(94.93 × 0.1) + (74.28 × 0.1) + (53.65 × 0.5 × 0.8)38.3815.35Basic consumables cost per visit—including dressing pack, sterile scissors, gloves, gauze, cleansing solution11.934.77Contact dressing—average cost between low and high‐cost dressings and different wound sizes19.357.74Absorbent layer—low‐cost absorbent layer1.060.42Compression wrap system38.9915.60Total costs per visit109.7143.88 Direct treatment SOC costs. The MPA device cost for 4 weeks of treatment for one leg at the time of this study was $1500 CAD. This study is based on the Cardiff RCT that used MPA for 4 weeks with SOC compression and then after 4 weeks continued with SOC compression alone. Projected Healing Rates and ICER The instantaneous exponential ulcer decay functions are used to calculate ulcer days (UD) in both treatment cohorts. Ulcer days are 234.90 for SOC and 178.28 for SOC and MPA. These amounts are calculated by integrating both ulcer survival functions over a 1 year or 365‐day period. As a result, ulcer free days (UFD) are 130.1 days for SOC and 186.7 for SOC and MPA. The positive increment in UFDs per patient with SOC and MPA is 56.6 days. The saving in clinical costs as a result of the 4 weeks of MPA therapy is calculated by multiplying the incremental number of UFDs (56.6) by the daily cost of dressings ($43.88), hence a saving of $2483.61. Four weeks of MPA costs $1500, hence there is a net cost saving of $983.61. This provides both benefit to the patient and a reduced cost to the system. The ICER is a cost reduction of $17.38 per UFD per patient. When only Direct Wound Care Costs are considered, the savings induced by a modest period of MPA therapy augmenting SOC and extrapolated over the larger population of patients with venous ulcers are highly beneficial to both the patient and to the healthcare system. The treatment costs were also calculated for the subset of patients whose VLUs remain unhealed for more than one year [38, 39, 40]. Based on Canadian cost estimates, annual Direct Wound Care Costs for a non‐healing VLU are approximately $16 016.20. If healing is achieved in 2 months using MPA, the projected cost drops to $5632.80, resulting in a direct cost savings of $10 383.40 per patient. The potential cost savings can be projected for both Ontario and for Canada based on populations of 16.1 million in Ontario and 41.5 million in Canada. A recently published systematic review and meta‐analysis of studies on the prevalence of VLU has reported a pooled prevalence of VLU from these studies of 0.32% [41]. Multiple studies have indicated that 20% or more of VLU remain unhealed at 1 year of treatment [38, 39, 40]. Using these data, the potential Direct Wound Care Cost savings for treating all patients with newly diagnosed VLU are $50.7 million in Ontario and $136.2 million in Canada (Table 2). For patients with VLUs unhealed for more than 12 months, projected savings rise to $106.3 million in Ontario and $275.8 million nationally, as shown in Table 2. These figures reflect only Direct Wound Care Cost savings to the healthcare system. TABLE 2Projected direct wound care cost savings per year in Ontario and Canada with the use of MPA to treat VLU.LocationPopulationVLU patientsCost savingsVLU > 12 monthsCost savingsOntario16.1 m51 5220 a $50.7 m10 240 b $106.3 mCanada41.5 m132 800 a $136.2 m26 560 b $275.8 m a Based on a prevalence of VLU of 0.32%. b Based on 20% of VLU not healed at 12 months. Projected direct wound care cost savings per year in Ontario and Canada with the use of MPA to treat VLU. Based on a prevalence of VLU of 0.32%. Based on 20% of VLU not healed at 12 months. Discussion This analysis is based on data from the Cardiff RCT, which showed that combining MPA with SOC approximately doubles the healing rate of venous leg ulcers (VLUs) compared to SOC alone. Using healing projections over 12 months based on this RCT, alongside Canadian treatment cost estimates, the model demonstrates that SOC and MPA leads to faster healing and an average increase of 56.6 UFDs per patient—a 43.5% improvement. When applied to Canadian Direct Wound Care Cost data, this results in an average Direct Wound Care Cost savings of $983.61 per patient. The incremental cost‐effectiveness ratio (ICER) reflects a cost reduction of $17.38 per additional UFD. This demonstrates a win‐win scenario for treating patients with VLU with SCO & MPA compared to using SOC alone. The treatment of these patients is predominantly in the community [19], which means that there is a financial benefit for the providers of home care who treat these patients, in utilizing this therapy for the first 4 weeks of treatment before the VLU becomes slow to heal or non‐healing. These benefits can result in more capacity for treating additional patients without having to employ more staff, or alternatively to reduce staffing and supply costs in order to treat the same number of patients. As part of this study, the authors aimed to determine the costs of treating patients with VLUs in outpatient settings in Canada. From consultation the authors determined the actual average frequency of treating VLUs, the average nursing costs and the average costs of the different types of dressings that are used. The goal was not to outline best practices but rather to capture the costs associated with common clinical practice. This paper has only looked at a subset of Direct Costs that relate to wound care costs of treating VLUs and has not included the Direct Institutional/System Costs or Indirect Costs (Societal Costs) [36]. This approach was taken so that the providers of home care could clearly identify the cost benefits to their budgets only, as well as the benefits to patients. Direct Institutional/System Costs come from the costs associated with investigations, treatment of infection and pain, or hospitalizations that occur in a small proportion of patients with VLUs. Indirect Costs come from the costs to patients related to loss of productivity, travel costs, medication costs and caregiver costs. Some of these costs were added to the UK cost‐effectiveness paper [34], which increased both the treatment costs and the cost savings. If these additional costs were added in the analysis in this paper, the cost savings in Canada would be greater. For the subset of patients with VLUs that remain unhealed for more than one year [38, 39, 40], on Canadian cost estimates, the savings in the Direct Wound Care Costs are projected to be $10 383.40 per patient. The impact of earlier healing of VLUs on patients cannot be overestimated. The potential risk of complications, other investigations, medical consultations and hospitalization are no longer present once the VLU has healed. Many studies have also emphasized the benefits in Quality of Life for patients once their VLU has healed [42, 43]. There is no source that documents the costs of treating VLUs in Canada. The costs that were arrived at in this paper were determined from data that could be collected across Canada on nursing costs, the type of nurses providing care, the frequency of dressings, and an average cost of the different components of dressing and bandaging for patients with VLUs. The authors' experience and knowledge of treating patients with VLUs, with input from other clinicians who provide wound care for VLUs, were used to determine the cost structure that has been provided in this paper. Some of the costs may be too low and conservative, some may be higher, but overall, the authors felt that this was a close estimate of the costs of treating VLUs in Canada. By way of comparison, a cost benefit paper that was conducted on UK costs based on the UK RCT [34], estimated the costs per patient treatment to be 110.86 GBP ($203.94 CAD) and when physician and laboratory costs were subtracted, the cost per visit was 74.31 GBP ($136.70 CAD approximately) compared to the estimated visit cost in this paper of $109.71 CAD. This comparison suggests a conservative, but similar estimate given differences in practices and materials used in the two countries. In this paper, the exponential function was used to forecast UDs for both treatment groups. A criticism of this technique is that the two‐parameter Weibull distribution is more representative of the ulcer healing trajectory, being more concave than the simple exponential curve. There were no data readily available that could be used to numerically estimate the two parameters of the Weibull distribution favoured by clinicians in the UK cost effectiveness paper [34]. More importantly, the actual difference in the SOC and SOC and MPA cumulative functions in an exponential curve is likely close to the difference of cumulative functions given the ulcer survival functions from Weibull distributions. The impact of a more representative ulcer survival function is then minimized [44]. Conclusion Based on healing data from the Cardiff RCT [33], combining MPA with SOC significantly accelerates VLU healing, yielding an average increase of 56.6 ulcer‐free days (43.5%) per patient. When Canadian treatment costs are applied and include the additional costs of 4 weeks of MPA treatment, SOC and MPA results in an average Direct Wound Care Cost savings of $983.61 per patient. This is in a population of patients with VLU without any additional complicating factors, and who are able to attend a nursing dressing clinic. The incremental cost‐effectiveness ratio (ICER) reflects a reduction of $17.38 per additional ulcer‐free day—demonstrating both clinical and economic benefit. These findings underscore the importance of ensuring access to MPA therapy plus SOC for VLU patients within community care settings nationwide in Canada. Funding The authors have nothing to report. Ethics Statement The authors have nothing to report. Conflicts of Interest Michael Stacey is a vascular surgeon and works as a consultant for biomedical companies including Perfuse Medtec. Connie Harris received a consultancy fee from Perfuse Medtec. Amanda Loney received a consultancy fee from Perfuse Medtec. Graham Corke received a consultancy fee from Perfuse Medtec.